key: cord-0709999-fq2gjf1v authors: Rosario, Pedro A.; McNaughton, Brian R. title: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex date: 2020-08-06 journal: bioRxiv DOI: 10.1101/2020.08.06.240333 sha: 5bb7e801ea5785b2797a9fef8204058202bf3ada doc_id: 709999 cord_uid: fq2gjf1v Infection and replication of SARS CoV-2 (the virus that causes COVID-19) requires entry to the interior of host cells. In humans, a Protein-Protein Interaction (PPI) between the SARS CoV-2 Receptor-Binding Domain (RBD) and the extracellular peptidase domain of ACE2, on the surface of cells in the lower respiratory tract, is an initial step in the entry pathway. Inhibition of the SARS CoV-2 RBD / ACE2 PPI is currently being evaluated as a target for therapeutic and/or prophylactic intervention. However, relatively little is known about the molecular underpinnings of this complex. Employing multiple computational platforms, we predicted ‘hot-spot’ residues in a positive control PPI (PMI / MDM2) and the CoV-2 RBD/ACE2 complex. Computational alanine scanning mutagenesis was performed to predict changes in Gibbs’ free energy that are associated with mutating residues at the positive control (PMI/MDM2) or SARS RBD/ACE2 binding interface to alanine. Additionally, we used the Adaptive Poisson-Boltzmann Solver to calculate macromolecular electrostatic surfaces at the interface of the positive control PPI and SARS CoV-2 / ACE2 PPI. Collectively, this study illuminates predicted hot-spot residues, and clusters, at the SARS CoV-2 RBD / ACE2 binding interface, potentially guiding the development of reagents capable of disrupting this complex and halting COVID-19. The novel coronavirus SARS-CoV-2 causes Coronavirus disease 19 (COVID-19), an established global health crisis. 1, 2 The COVID-19 pandemic continues to take a significant toll on the global economy and healthcare infrastructure, and is attributed to more than 700,000 deaths worldwide; over 160,000 in the United States of America alone. The number of infections, and resulting COVID-19-related deaths continues to grow at a staggering rate. Older individuals, and those with pre-existing conditions, are at the highest risk of death as a result of deleterious consequences related to SARS-CoV-2 infection. Moreover, negative outcomes associated with SARS-CoV-2 infection disproportionately correlate with minorities, likely due to a number of factors. 3 The magnitude of the COVID-19 pandemic has triggered a global response from researchers to identify therapeutics and/or prophylaxis capable of inhibiting, or slowing, infection and propagation of this deadly disease. SARS-CoV-2 must enter host cells to replicate. Previous studies on SARS-CoV, which is closely related to SARS-CoV-2, provided insight into the mechanism of cell entry. As an early step in the cell entry mechanism, the viral spike protein (S) on the surface of SARS-CoV binds the extracellular protease domain (PD) of angiotensin-converting enzyme 2 (ACE2), a protein on the surface of multiple cells, including cells in the lower respiratory tract. [4] [5] [6] [7] This recognition event is followed by membrane fusion leading to host cell entry. It was recently shown that SARS-CoV-2 also relies on an interaction between its spike protein and ACE2 to gain entry to the interior of human cells. Cryo-electron microscopy (cryo-EM) structural analysis of the complex involving the SARS-CoV-2 spike protein Receptor Binding Domain (RBD) and human ACE2 was recently reported (PDB code: 6M17), with an overall resolution of 2.9 Å and local resolution of 3.5 Å at the RBD / ACE2 binding interface (Figure 1a) . 8 Given the important role the Protein-Protein Interaction (PPI) between SARS-CoV-2 RBD and ACE2 plays in host cell entry, inhibition of this PPI has received attention as a target for therapeutic and/or prophylactic intervention. 9, 10 Regions on ACE2 closest to SARS-CoV-2 include the α1-helix (Figure 1b , blue) α2-helix (Figure 1b , orange) and the β3-β4 loop (Figure 1b, green) . Researchers have shown that a 23 residue peptide, consisting of ACE2 α1-helix sequence (I21-S43) tightly binds SARS-CoV-2 (KD ~50 nM). 10 However, relatively little is known about the molecular underpinnings that stabilize the SARS-CoV-2 / ACE2 complex. In an era when academic laboratories have been closed, or severely limited due to the COVID-19 pandemic, we sought to use multiple computational platforms, with an emphasis on servers that are available online to all researchers, to study the SARS-CoV-2 RBD / ACE2 complex examine the electrostatics and topology of the interface, and identify "hot-spots" -amino acids, or clusters thereof, that significantly contribute to the binding free energy of this therapeutically-relevant PPI. We used the Knowledge-based FADE and Contacts 2 (KFC-2), a free server that compares favorably to Robetta, FOLDEF, HotPoint, and MINERVA, to predict hot-spot residues and/or clusters at the SARS-CoV-2/ACE2 binding interface. 11, 12 As a positive control in our study, we performed an analogous examination of the PMI / MDM2 complex (PDB code: 3EQS, Figure 1a) , which is well studied. 13 PDB files for these two complexes were loaded into the server, which revealed hot-spot residues at each interface. KFC accurately predicted hot-spot residues on the PMI peptide, which have been experimentally validated (Figure 2a) . 13 Specifically, residues F3, Y6, W7, and L10 were identified as hot-spot residues on the PMI peptide. Complimentary hot-spot residues L54, V75, V93, and I99 were identified as hot-spot residues on MDM2 (Figure 2a- were identified on SARS-CoV-2 RBD and T27, H34, D38, Y41, and K353 were identified on ACE2. For both complexes, KFC-a values were used, as these have been shown to have superior predictability outcomes compared to KFC-b values. 12 Satisfyingly, four of the five predicted hot-spot residues on ACE2 (T27, H34, D38, and Y41) are found on the α1-helix (Figure 1b , blue), and researchers have shown that this helix alone (as a chemically synthesized 23 residue peptide) binds SARS-CoV-2 RBD with a dissociation constant of ~50 nM. 10 Lysine 353 was also identified as a hot-spot residue, and is on the β3-β4 loop that neighbors the α1-helix (Figure 2d ). When paired with experimental results, demonstrating high affinity between ACE2 α1-helix and SARS-CoV-2 RBD, these results suggest that KFC-2 correctly identified residues at the interface critical to stability of the complex. We next used BAlaS 14, 15 , a computational alanine scanning mutagenesis server, to predict the change in free energy (ΔΔG) associated with mutating interface residues to alanine. Our analysis focused on residues within 13 Å from the binding interface (set as default) and residues plotted in BAlaS analysis of the SARS-CoV-2/ACE2 complex resulted in the prediction of seven residues on ACE2 that contribute to the binding free energy of the complex (Figure 3c-d) . The following residues, and associated changes in free energy, were identified: (Figure 3cd) . As was the case with the initial hot-spot prediction, the majority of the residues predicted to stabilize the complex are on the α1-helix (D30, K31, H34, D38, Y41). As in the KFC-2 hot-spot prediction, K353, which is found in the β3-β4 loop that flanks the α1helix, was predicted as a stabilizing residue in the complex. Tyrosine 83, in the α2-helix (Figure 1b, Figure 3c-d) , was also predicted as a contributor to complex stability. Predicted changes in binding free energies for all computational mutations, for both PMI / MDM2 and SARS-CoV-2 / ACE2, are available in the Supporting Information ( Figure S2 ). We used the Adaptive Poisson-Botzmann Solver (APBS) 16 to generate electrostatic potential maps for the solvent-exposed surfaces of our positive control PPI (PMI/MDM2) and the SARS-CoV-2 RBD complex. As seen in Figure 4a -b, the positive control interaction is consistent with many PPIs, the driving factor for the PMI/MDM2 interaction is burying large, hydrophobic residues (most notably F3, W7, and L10) into a well-defined, largely hydrophobic, binding pocket. This results in relatively large changes in Gibbs' free energy, as a result of beneficial changes in entropy (desolvation) and enthalpy (e.g. van der Waals interactions, π-π stacking). The binding face of the SARS-CoV-2 RBD / ACE2 complex (Figure 4a) was characterized as well. The binding surface of ACE2 has a pronounced patch with increased hydrophobic character, relative to the remainder of the surface, which aligns with the α1-helix (Figure 4d) . Likewise, SARS-CoV-2 RBD presents a relatively shallow binding pocket with hydrophobic character, into which the α1-helix rests (Figure 4d) . In contrast to the PMI / MDM2 complex, neither the ACE2 or SARS-CoV-2 surface contain deep, largely hydrophobic binding pockets. Collectively, this supports our hot-spot and computational alanine scanning mutagenesis studies. Compared to PMI / MDM2, more residues participate in stabilizing the complex; however, the magnitude of predicted stabilization is lower for each residue in the SARS-CoV-2 / ACE2 complex, compared to PMI / MDM2. We hypothesize that this is likely due to decreased burying of hydrophobic residues in the former, and increased hydrogen bonding and/or ion-paired interactions to stabilize the complex, relative to the later. KFC-2 hot-spot prediction revealed five residues each on ACE2 and SARS-CoV-2 RBD that are predicted to stabilize the complex; computational alanine scanning with BAlaS predicted seven residues on each protein, which when mutated, significantly alter binding energy. There is good agreement between the two methods; both servers predicted ACE2 residues H34, D38, Y41, and K353, and SARS-CoV-2 RBD residues Y489, Q498, and Y505 as important for complex stability (Figure 5 , residues highlighted with an asterisk). Interestingly, while the structure of SARS-CoV RBD aligns well with SARS-CoV-2 RBD, with a root mean squared deviation (RMSD) of 0.68 Å over 139 pairs of Cα atoms 8 , mutations exist, including interface residues predicted here to stabilize SARS-CoV-2 RBD interactions with ACE2. For example, Y484®Q498, L443®F456, N479®Q493, and L472®F486 mutations at equivalent positions of SARS-CoV RBD and SARS-CoV-2 RBD, respectively, are observed. 7, 8 These mutations may change the affinity between SARS-CoV-2 for ACE2, relative to SARS-CoV, and likely alters the hot-spot geographies on the binding surface of SARS-CoV-2 RBD, compared to SARS-CoV. Electrostatic potential and topology of ACE2 and SARS-CoV-2 RBD surface areas that engage one another in the complex. Colored from -25 kT/e (red) to +25 kT/e (blue). A Novel Coronavirus from Patients with Pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities Coronavirus spike proteins in viral entry and pathogenesis Characterization of severe acute respiratory syndromeassociated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv An automated decision-tree approach to predicting protein interaction hot spots KFC2: a knowledge-based hot spot prediction method based on interface solvation, atomic density, and plasticity features Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions BAlaS: fast, interactive and accessible computational alaninescanning using BudeAlaScan Predicting and Experimentally Validating Hot-Spot Residues at Protein-Protein Interfaces Electrostatics of nanosystems: application to microtubules and the ribosome We acknowledge Delaware State University for institutional support and the Delaware INBRE program, which is supported by a grant from the National Institute of General Medical Sciences (NIGMS, P20 GM103446) from the National Institutes of Health and the State of Delaware.